Pharmacovigilance and Safety Biomarkers

In case you missed it, view our slides and recording in which pharmacovigilance experts from Springer Nature joined biomarker experts from Amplion to discuss the growing importance of a biomarker strategy in pharmacovigilance, part 2.

What you will learn:

  • The utility of safety biomarkers throughout the drug development process
  • The regulatory framework for biomarker qualification
  • Insight into how to identify biomarker information from the literature
  • The role of biomarkers in post-marketing pharmacovigilance practices




Kerryn Kilkenny

Content Development Manager, Adis Business Intelligence at Springer Nature

Inspired by innovation and providing value to customers, Kerryn has worked creating novel solutions for pharmaceutical companies for over 17 years. Working globally with clients in Europe, the US and Asia Pacific has provided Kerryn with insight into an array of pharmaceutical and healthcare environments and an understanding of the content and solutions available to meet different information needs.


Seth Taylor

Head of Product and Marketing at Amplion

As an enterprise software entrepreneur, Seth’s career has included co-founding a recruiting software company, and Workday, a huge success in the burgeoning SaaS enterprise software space. Seth is excited to see Amplion contribute to the realization of the promise of personalized medicine.

Seth writes actively on topics related to biomarkers and personalized medicine at our blog Biomarker Trends.

To learn more about Amplion, Springer Nature and our new relationship: